Rituximab-Based Regimen As First-Line Treatment in Chinese Patients with Follicular Lymphoma: Three-Year Safety Data from a Prospective, Observational Study

被引：0
|
作者：
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
Feng, Jifeng
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5167
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Healthcare utilization and costs associated with first-line treatment with obinutuzumab- and rituximab-based regimens for follicular lymphoma.
    Ta, Jamie T.
    To, Tu My
    Sud, Cheryl
    Shapouri, Sheila
    Seetasith, Arpamas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
    Zucca, Emanuele
    Rondeau, Stephanie
    Vanazzi, Anna
    Ostenstad, Bjorn
    Mey, Ulrich J. M.
    Rauch, Daniel
    Wahlin, Bjorn E.
    Hitz, Felicitas
    Hernberg, Micaela
    Johansson, Ann-Sofie
    Brown, Peter de Nully
    Hagberg, Hans
    Ferreri, Andres J. M.
    Lohri, Andreas
    Novak, Urban
    Zander, Thilo
    Bersvendsen, Hanne
    Bargetzi, Mario
    Mingrone, Walter
    Krasniqi, Fatime
    Dirnhofer, Stefan
    Hayoz, Stefanie
    Hawle, Hanne
    Vilei, Simona Berardi
    Ghielmini, Michele
    Kimby, Eva
    Caspar, Clemens
    Koberle, Dieter
    Novak, Urban
    Zenhausern, Reinhard
    Jost, Lorenz M.
    Mach, Nicolas
    Voegeli, Michele
    Tscherry, Georg
    Fischer, Natalie
    Burkhard, Roger
    Schmid, Mathias
    Panagiotis, Samaras
    Munksgaard, Lars
    Hernberg, Micaela
    Vasala, Kaija
    Lehtinen, Tuula
    Jyrkkio, Sirkku
    Ekanger, Roald
    Rolke, Jurgen
    Meyer, Peter
    Maisenholder, Martin
    Eidem, Monika
    Radlund, Anders
    Lagerlof, Ingemar
    BLOOD, 2019, 134 (04) : 353 - 362
  • [3] SAFETY AND EFFICACY OF RITUXIMAB AND CHLORAMBUCIL IN COMBINATION AS FIRST-LINE TREATMENT IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS
    Martinelli, G.
    Andreola, G.
    Laszlo, D.
    Minga, P.
    Cannella, L.
    Liptrott, S.
    Sammassimo, S.
    Linetti, M.
    Calabrese, L.
    Bassi, S.
    HAEMATOLOGICA, 2012, 97 : 651 - 652
  • [4] Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma
    De la Cruz Vicente, Fatima
    Carrillo-Cruz, Estrella
    Sole Rodriguez, Maria
    Marin Niebla, Ana
    Martino Galiana, Maria Luz
    Falantes Gonzalez, Jose
    Montero Cuadrado, Isabel
    Gonzalez Campos, Jose
    Espigado Tocino, Ildefonso
    Rios-Herranz, Eduardo
    Antonio Perez-Simon, Jose
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) : 469 - 475
  • [5] A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
    Feng, Jifeng
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Feng, Ru
    Wang, Wei
    Niu, Zuoxing
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changing
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    BLOOD, 2014, 124 (21)
  • [6] The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
    Kimby, Eva
    Lockmer, Sandra
    Holte, Harald
    Hagberg, Hans
    Wahlin, Bjorn E.
    Brown, Peter
    Ostenstad, Bjorn
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) : 738 - 747
  • [7] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
    Wu, Jian-Qiu
    Song, Yong-Ping
    Su, Li-Ping
    Zhang, Ming-Zhi
    Lis, Wei
    Hu, Yu
    Zhang, Xiao-Hong
    Gao, Yu-Huan
    Niu, Zuo-Xing
    Feng, Ru
    Wang, Wei
    Peng, Jie-Wen
    Li, Xiao-Lin
    Ouyang, Xue-Nong
    Wu, Chang-Ping
    Zhang, Wei-Jing
    Zeng, Yun
    Xiao, Zhen
    Liang, Ying-Min
    Zhuang, Yong-Zhi
    Wang, Ji-Shi
    Sun, Zi-Min
    Bai, Hai
    Cui, Tong-Jian
    Feng, Ji-Feng
    CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1767 - 1775
  • [8] Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma
    Feng, Jifeng
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Niu, Zuoxing
    Feng, Ru
    Wang, Wei
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changping
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    BLOOD, 2017, 130
  • [9] Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Dawson, Keith L.
    Masaquel, Anthony S.
    Seetasith, Arpamas
    BLOOD, 2019, 134
  • [10] Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study
    Ekaterina, Nesterova
    Kravchenko, Sergey K.
    Kovrigina, Alla M.
    Plastinina, Lubov V.
    Mangasarova, Yana K.
    Gorenkova, Liliya
    Vorobyev, Vladimir
    Mariin, Dmitriy
    Baryakh, Elena A.
    Polyakov, Yuriy
    Zeynalova, Pervin
    Volodicheva, Elena
    Glonina, Nataliya
    Savchenko, Valeriy G.
    BLOOD, 2017, 130
12345